Anika Therapeutics, Inc. (ANIK)
| Market Cap | 207.71M |
| Revenue (ttm) | 112.82M |
| Net Income (ttm) | -10.88M |
| Shares Out | 13.40M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | 62.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,601 |
| Open | 15.86 |
| Previous Close | 15.85 |
| Day's Range | 15.52 - 15.98 |
| 52-Week Range | 7.87 - 16.24 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 17.00 (+9.68%) |
| Earnings Date | Apr 29, 2026 |
About ANIK
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and ... [Read more]
Financial Performance
In 2025, Anika Therapeutics's revenue was $112.82 million, a decrease of -5.91% compared to the previous year's $119.91 million. Losses were -$10.88 million, -80.70% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ANIK stock is "Buy" and the 12-month stock price target is $17.0.
News
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue it...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early int...
Top 2 Health Care Stocks That May Crash This Quarter
As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Anika Therapeutics Transcript: 2026 CG Musculoskeletal Conference
The conference highlighted a robust hyaluronic acid-based product portfolio, strong commercial growth, and a focus on expanding regenerative solutions. Regulatory progress for Hyalofast and Cingal, along with disciplined R&D and operational improvements, support a positive outlook.
Anika Therapeutics Earnings Call Transcript: Q4 2025
Commercial channel revenue grew strongly in 2025, offsetting OEM declines from U.S. pricing pressures. 2026 guidance projects 1–9% revenue growth, with commercial channel expected to rise 10–20% and continued investment in innovation and operational efficiency.
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 mil...
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, Pr...
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Anika (ANIK) To Contact Him Directly To Discuss Their Options
Anika Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw 6% revenue decline due to OEM pricing pressure, but commercial channel revenue grew 22% year-over-year, driven by Integrity and international OA Pain Management. Gross margin improved sequentially, and strong cash flow supported a new $15M share repurchase.
Anika Reports Third Quarter 2025 Financial Results
Commercial Channel revenue up 22% with continued strong Integrity ™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module ...
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...
Anika Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 8% year-over-year, but regenerative solutions grew 41% led by Integrity. Hyalofast missed coprimary endpoints but hit key secondary endpoints, with PMA submission planned and commercial launch delayed to 2027. Strong liquidity and cost controls maintained.
Anika Reports Second Quarter 2025 Financial Results
Regenerative Solutions revenue up 41% with Integrity ™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to mor...
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...
Anika Therapeutics Earnings Call Transcript: Q1 2025
Q1 2025 saw 18% commercial channel growth and strong Integrity performance, but total revenue fell 10% due to OEM pricing pressure. Gross margin declined to 56%, with manufacturing and pricing challenges impacting profitability, though improvements are expected in H2 2025.
Anika Reports First Quarter 2025 Financial Results
First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones...
Anika to Participate in the Sidoti Virtual Investor Conference
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on earl...
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025
BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue it...
Anika Therapeutics Earnings Call Transcript: Q4 2024
Divestitures of Arthrosurface and Parcus Medical refocused the business on core HA products, driving strong commercial channel growth and international OA pain management gains. Integrity and pipeline progress support a positive outlook, though OEM revenue faces U.S. pricing pressure.
Anika Reports Fourth Quarter and Full Year 2024 Financial Results
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Co...
Anika Therapeutics Transcript: CG 2025 Musculoskeletal Conference
A strategic refresh is driving expansion into a $3+ billion addressable market, with strong growth from leading osteoarthritis and regenerative products. New launches like Hyalofast and Cingal are set to accelerate revenue, supported by robust clinical data and a strong financial position.
Anika Completes Divestiture of Parcus Medical
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio Execution of Previously Announced Plan Sharpens Focu...
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its...